Phase IIa Trial Evaluating the Safety of Intratumoral Injection of NanoPac® in Subjects With Locally Advanced Pancreatic Adenocarcinoma

Trial Profile

Phase IIa Trial Evaluating the Safety of Intratumoral Injection of NanoPac® in Subjects With Locally Advanced Pancreatic Adenocarcinoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Adverse reactions
  • Sponsors Nanology
  • Most Recent Events

    • 11 Aug 2017 Status changed from not yet recruiting to recruiting.
    • 12 Jun 2017 Planned initiation date changed from 1 May 2017 to 1 Jun 2017.
    • 15 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top